CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) TREATMENT MARKET ANALYSIS

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market, by Treatment Type (Corticosteroids, Intravenous Immunoglobulin Therapy, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI2609
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Regional Analysis

North America is expected to hold a dominant position in the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market. Factors such as initiatives from governments and other organizations are expected to have an influence on the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For instance, in April 2019, Guillain-Barre syndrome & Chronic Inflammatory Demyelinating Polyneuropathy (GBS | CIDP) international foundation announced that it is going to celebrate May as GBS | CIDP awareness month. They plan to create awareness about the foundation’s legislative initiatives for CIDP patients through social media and campaigns. The initiative is for creating a bill which includes the establishment of the Medicare Part B Home Infusion Demonstration Project, and increase in funds for treatment of CIDP patients. These factors are expected to have a positive impact on the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.